In a double blinded placebo controlled phase 3 study, obese patients were treated with either daily Rybelsus (50 mg) or placebo for 68 weeks
Treated animals often exhibit reductions in circulating triglycerides and LDL cholesterol, along with lower levels of hepatic steatosis (fat accumulation in the liver)
Schedule It: Pick the same day and time each week so your new habit sticks
But in 2026 it feels like were approaching an inflection point as millions of people have used a GLP-1 medication and are reporting all sorts of benefits beyond just weight loss and control of their diabetes
Patients who notice significant mood changes after starting these medications should discuss them with their doctor

Key findings Related Stories Medically tailored grocery deliveries improve blood sugar control among diabetes patients Cleveland Clinic study links gut microbe byproduct to heart arrhythmia High doses of caffeine from energy drinks cause cardiovascular harm Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Below is a Q&A with study senior author Dr